Diagnoses and Treatment Recommendations—Interrater Reliability of Uroflowmetry in People with Multiple Sclerosis
-
Published:2024-07-18
Issue:7
Volume:12
Page:1598
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Jaekel Anke K.12ORCID, Rieger Julia1, Butscher Anna-Lena2ORCID, Möhr Sandra3ORCID, Schindler Oliver4ORCID, Queissert Fabian5ORCID, Hofmann Aybike6ORCID, Schmidt Paul7ORCID, Kirschner-Hermanns Ruth12, Knüpfer Stephanie C.12
Affiliation:
1. Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany 2. Department of Neuro-Urology, Johanniter Rehabilitation Centre Godeshoehe, 53177 Bonn, Germany 3. Clinic for Neurorehabilitation and Paraplegiology, REHAB Basel, 4055 Basel, Switzerland 4. Clinic for Urology, University Hospital Ulm, 89070 Ulm, Germany 5. Clinic for Urology, University Hospital Münster, 48149 Münster, Germany 6. Clinic St. Hedwig, Department of Paediatric Urology, University Medical Center Regensburg, 93053 Regensburg, Germany 7. Statistical Consulting for Science and Research, Berlin Statistical Consulting for Science and Research, 13086 Berlin, Germany
Abstract
Background: Uroflowmetry (UF) is an established procedure in urology and is recommended before further investigations of neurogenic lower urinary tract dysfunction (NLUTD). Some authors even consider using UF instead of urodynamics (UD). Studies on the interrater reliability of UF regarding treatment recommendations are rare, and there are no relevant data on people with multiple sclerosis (PwMS). The aim of this study was to investigate the interrater reliability (IRR) of UF concerning diagnosis and therapy in PwMS prospectively. Methods: UF of 92 PwMS were assessed by 4 raters. The diagnostic criteria were normal findings (NFs), detrusor overactivity (DO), detrusor underactivity (DU), detrusor–sphincter dyssynergia (DSD) and bladder outlet obstruction (BOO). The possible treatment criteria were as follows: no treatment (NO), catheter placement (CAT), alpha-blockers, detrusor-attenuating medication, botulinum toxin (BTX), neuromodulation (NM), and physiotherapy/biofeedback (P/BF). IRR was assessed by kappa (κ). Results: κ of diagnoses were NFs = 0.22; DO = 0.17; DU = 0.07; DSD = 0.14; and BOO = 0.18. For therapies, the highest κ was BTX = 0.71, NO = 0.38 and CAT = 0.44. Conclusions: There is a high influence of the individual rater. UD should be subject to the same analysis and a comparison should be made between UD and UF. This may have implications for the value of UF in the neuro-urological management of PwMS, although at present UD remains the gold standard for the diagnostics of NLUTD in PwMS.
Funder
’Förderverein zur Kontinenzforschung und Kontinenzaufklärung e. V.‘ Open Access Publication Fund of the University of Bonn
Reference36 articles.
1. How can we maximize the diagnostic utility of uroflow?: ICI-RS 2017;Gammie;Neurourol. Urodyn.,2018 2. Radmayr, C., Bogaert, G., Bujons, A., Burgu, B., Castagnetti, M., ‘t Hoen, L.A., O’Kelly, F., Pakkasjärvi, N.A., Quadackers, J., and Rawashdeh, Y.F.H. (2023). EAU Guidelines on Paediatric Urology, EAU Guidelines Office. Available online: https://uroweb.org/guidelines/paediatric-urology. 3. Cornu, J.N., Gacci, M., Hashim, H., Herrmann, T.R.M., Malde, S., Netsch, C., De Nunzio, C., Rieken, M., Sakalis, V., and Tutolo, M. (2023). EAU Guidelines on Managemnt of Non-Neurogenic Male LUTS, EAU Guidelines Office. Available online: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts. 4. Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure-flow studies;Abrams;Neurourol. Urodyn.,2002 5. Harding, C.K., Lapitan, M.C., Arlandis, S., Bø, K., Cobussen-Boekhorst, H., Costantini, E., Groen, J., Nambiar, A.K., Omar, M.I., and Peyronnet, B. (2023). EAU Guidelines on Management of Non-Neurogenic Female LUTS, EAU Guidelines Office. Available online: https://uroweb.org/guidelines/non-neurogenic-female-luts.
|
|